Browse

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

The rejection may make the pharma firms remaining lawsuits more difficult.

The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another